FBR Capital Starts NantHealth (NH) at Outperform

FBR Capital initiates coverage on NantHealth (NASDAQ: NH) with a Outperform rating and a price target of $18.00.

Analyst Steven Halper commented, "We initiate coverage of NantHealth, LLC (NH) with an Outperform rating. NantHealth is an evidence-based, personalized healthcare company that aims to improve patient outcomes and more effectively treat diseases. Within its ecosystem of applications, the company's GPS Cancer screening test is poised to change how cancer is treated. Its proprietary technology (licensed from privately held NantOmics) enables the diagnosis of tumors at the molecular level by measuring the genome and proteomes of tumors, thereby predicting potential responses to drug therapies. The company has secured reimbursement from a select number of payors and continues to develop new relationships. We believe NH is poised for rapid growth. Our price target is $18 per share, representing about 40% upside from current levels. Arguably, there are many uncertainties regarding future performance, but we believe the discount rate assumption in our DCF model adequately reflects the risk in the company's ability to achieve our estimates."

For an analyst ratings summary and ratings history on NantHealth click here. For more ratings news on NantHealth click here.

Shares of NantHealth closed at $12.71 yesterday.

You May Also Be Interested In